Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source
Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane +19 more
wiley +1 more source
Community-based primary care approaches to supporting families of children with developmental disabilities: Experts' perspectives using the capabilities framework. [PDF]
Magidigidi-Mathiso L +2 more
europepmc +1 more source
Aquaporin‐4 in Narcolepsy Type 1: Investigation of Perivascular Fluid Movement in Sleep Disorders
ABSTRACT Narcolepsy type 1 (NT1) is caused by the loss of hypocretin‐1 leading to excessive daytime sleepiness and cataplexy. Additionally, disrupted nighttime sleep has become an increasingly recognized feature of NT1. As the glymphatic fluid movement has been linked to sleep architecture, we investigated cerebrospinal fluid (CSF) Aquaporin‐4 (AQP4 ...
Jonas Ranke +5 more
wiley +1 more source
Enhancing Radiation Therapy Technologists' (RTTs) autonomy in IGRT through structured training: a Protocol for a Quality Improvement Project. [PDF]
Boriani M +9 more
europepmc +1 more source
Co-designing a structured referral template to enhance dementia diagnosis: a modified e-Delphi study. [PDF]
Cronin M +16 more
europepmc +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
Advancing forensic psychiatry in Rwanda: lessons learned and challenges. [PDF]
D'Orta I +6 more
europepmc +1 more source
Liangkang Ni on Husserl and Buddhism: a comparative phenomenological analysis. [PDF]
Gutland C, Liu H.
europepmc +1 more source
Artificial Intelligence and Large Language Models: Editorial Reflections. [PDF]
Alanoğlu Z +3 more
europepmc +1 more source

